Last reviewed · How we verify
NCT04339036: CapTemY90
CapTemY90 for Grade 2/3 NET Liver Metastases
Phase 2 trial testing Capecitabine Oral Product in Neuroendocrine Tumor Grade 2 in 70 participants. Currently enrolling.
1 May 2026
Quick facts
| Lead sponsor | Abramson Cancer Center at Penn Medicine |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 7 October 2021 |
| Primary completion | 1 May 2026 |
| Estimated completion | 1 May 2026 |
| Sites | 4 locations across United States |
Drugs / interventions tested
- Capecitabine Oral Product — full drug profile →
- Temozolomide Oral Product — full drug profile →
- transarterial radioembolization
Conditions studied
- Neuroendocrine Tumor Grade 2 — all drugs for Neuroendocrine Tumor Grade 2 →
- Neuroendocrine Tumors — all drugs for Neuroendocrine Tumors →
Sponsor
Abramson Cancer Center at Penn Medicine — full company profile →
Who can join
18 and older, any sex, with Neuroendocrine Tumor Grade 2 or Neuroendocrine Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Chemotherapy in Well Differentiated Neuroendocrine Tumors (NET) G1, G2, and G3: A Narrative Review.
Zappi A, Persano I, Galvani L, Parlagreco E, et al · · 2023 · cited 22× · PMID 36675645 · DOI 10.3390/jcm12020717 -
The Evolving Role of Radioembolization in the Treatment of Neuroendocrine Liver Metastases.
Ramdhani K, Braat AJAT. · · 2022 · cited 20× · PMID 35884479 · DOI 10.3390/cancers14143415 -
Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors.
McClellan K, Chen EY, Kardosh A, Lopez CD, et al · · 2022 · cited 12× · PMID 36230691 · DOI 10.3390/cancers14194769 -
Overview of Ongoing Clinical Trials on Radioembolization.
Fabritius MP, Ricke J. · · 2022 · cited 7× · PMID 36184696 · DOI 10.1007/s00270-022-03270-4 -
Chemoembolization Beyond Hepatocellular Carcinoma: What Tumors Can We Treat and When?
DePietro DM, Li X, Shamimi-Noori SM. · · 2024 · cited 2× · PMID 38495263 · DOI 10.1055/s-0043-1777716 -
ArTisaN trial protocol: a single Centre, open-label, phase II trial of the safety and efficacy of TheraSphere selective internal radiation therapy (SIRT) in the treatment of inoperable metastatic (liver) neuroendocrine neoplasia (NENs).
Sharma R, Slater S, Evans J, Martinez M, et al · · 2022 · cited 1× · PMID 35858849 · DOI 10.1186/s12885-022-09859-9
Verify or expand the search:
- PubMed search for NCT04339036
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Capecitabine Oral Product
Trials testing the same drug.
- NCT04263298 — Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastat · Phase 3 · recruiting
- NCT03428529 — Capecitabine Versus Bolus 5-Fu Associated to Radiotherapy as Neoadjuvant Treatment for Rectal Cancer. · Phase 2, PHASE3 · completed
Other recruiting trials for Neuroendocrine Tumor Grade 2
Currently open trials in the same condition.
- NCT06855095 — Absorbed Tumor Dose in Peptide Receptor Radionuclide Therapy with Long-acting Somatostatin Analogues - ATSA Trial · Phase 2, PHASE3 · recruiting
- NCT06395402 — 177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry · Phase 2 · recruiting
- NCT06472388 — Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors · Phase 2 · recruiting
- NCT06148636 — A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors · EARLY_PHASE1 · active not recruiting
- NCT05111509 — A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent · EARLY_PHASE1 · active not recruiting
Other Abramson Cancer Center at Penn Medicine trials
Trials by the same sponsor.
- NCT07478848 — Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas · Phase 1 · not yet recruiting
- NCT07059611 — Neoadjuvant Intra-tumoral RP2 and FLOT in Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
- NCT07454499 — Engaging M-health for Symptom Monitoring and Health Promotion for Women on Endocrine Therapy for Breast Cancer (EmSHAPE) · NA · not yet recruiting
- NCT07222241 — Comparing Numbing Techniques in Mohs Micrographic Surgery · NA · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04339036 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine
- Last refreshed: 10 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04339036.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing